Why the study?
Does pyridostigmine bromide alter electrocardiographic variables such as QTc dispersion in healthy young individuals?
Does pyridostigmine bromide alter electrocardiographic variables such as QTc dispersion in healthy young individuals?
Answers are grounded in this paper and cite their sources.
Pyridostigmine bromide reduces QTc dispersion and increases RR intervals in healthy individuals, suggesting a potential cardioprotective mechanism via cholinergic stimulation.
OBJECTIVE: Parasympathetic dysfunction is an independent risk factor in individuals with coronary artery disease, and cholinergic stimulation is a potential therapeutical option. We determined the effects of pyridostigmine bromide, a reversible anticholinesterase agent, on electrocardiographic variables of healthy individuals. METHODS: We carried out a cross-sectional, double blind, randomized, placebo-controlled study. We obtained electrocardiographic tracings in 12 simultaneous leads of 10 healthy young individuals at rest before and after oral administration of 45 mg of pyridostigmine or placebo. RESULTS: Pyridostigmine increased RR intervals (before: 886+/-27 ms vs. after: 1054+/-37 ms) and decreased QTc dispersion (before: 72+/-9 ms vs. after: 45+/-3 ms), without changing other electrocardiographic variables (PR segment, QT interval, QTc, and QT dispersion). CONCLUSION: Bradycardia and the reduction in QTc dispersion induced by pyridostigmine may effectively represent a protective mechanism if these results can be reproduced in individuals with cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Castro et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: